Diastolic dysfunction laboratory findings
Jump to navigation
Jump to search
|
Diastolic dysfunction Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Diastolic dysfunction laboratory findings On the Web |
|
American Roentgen Ray Society Images of Diastolic dysfunction laboratory findings |
|
Risk calculators and risk factors for Diastolic dysfunction laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shankar Kumar, M.B.B.S. [2]
Overview
The initial laboratory tests in diastolic dysfunction or failure include complete blood count, urinalysis, serum electrolytes, blood urea nitrogen, serum creatinine, fasting blood glucose (glycohemoglobin), lipid profile, liver function tests, and thyroid-stimulating hormone. The measurement of BNP is done only when diagnosis is unclear.
Laboratory Findings
Plasma brain natriuretic peptide (BNP) or N-terminal pro b-type natriuretic peptide (NT-proBNP) can be used to diagnose heart failure when diagnosis is unclear. BNP levels are lower in diastolic dysfunction when compared with systolic dysfunction[1].
Diagnostic Criteria Using BNP
Suggested cutpoints for the diagnosis of diagnostic heart failure are BNP >100 pg/mL or NT-proBNP >300 pg/mL. In addition, BNP >100 pg/mL and NT-proBNP >300 pg/mL are independent predictors of adverse cardiovascular events in patients with heart failure with preserved left ventricular ejection fraction[2].
ACC/AHA 2009 Guidelines for the Diagnosis and Management of Chronic Heart Failure in the Adult[3][4]
Initial Clinical Assessment Recommendation
| Class I |
| " 1. Initial laboratory evaluation of patients presenting with heart failure should include complete blood count, urinalysis, serum electrolytes (including calcium and magnesium), blood urea nitrogen, serum creatinine, fasting blood glucose (glycohemoglobin), lipid profile, liver function tests, and thyroid-stimulating hormone. (Level of Evidence: C) " |
| Class III (No Benefit) |
| "1. Routine measurement of circulating levels of neurohormones (e.g., norepinephrine or endothelin) is not recommended for patients presenting with heart failure. (Level of Evidence: C) " |
| Class IIa |
| " 1. Measurement of B-type natriuretic peptide (BNP) can be useful in the evaluation of patients presenting in the urgent care setting in whom the clinical diagnosis of heart failure is uncertain. Measurement of natriuretic peptides (BNP and NT-proBNP) can be useful in risk stratification.[5][6][7][8][9][10][11][12] (Level of Evidence: A) " |
| "2. Screening for hemochromatosis, sleep-disturbed breathing, or human immunodeficiency virus is reasonable in selected patients who present with heart failure. (Level of Evidence: C) " |
| "3. Diagnostic tests for rheumatologic diseases, amyloidosis, or pheochromocytoma are reasonable in patients presenting with heart failure in whom there is a clinical suspicion of these diseases. (Level of Evidence: C) " |
Serial Clinical Assessment Recommendation
| Class IIb |
| "1. The value of serial measurements of BNP to guide therapy for patients with heart failure is not well established. (Level of Evidence: C) " |
References
- ↑ Maisel AS, McCord J, Nowak RM, Hollander JE, Wu AH, Duc P; et al. (2003). "Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the Breathing Not Properly Multinational Study". J Am Coll Cardiol. 41 (11): 2010–7. PMID 12798574.
- ↑ Grewal J, McKelvie RS, Persson H, Tait P, Carlsson J, Swedberg K; et al. (2008). "Usefulness of N-terminal pro-brain natriuretic Peptide and brain natriuretic peptide to predict cardiovascular outcomes in patients with heart failure and preserved left ventricular ejection fraction". Am J Cardiol. 102 (6): 733–7. doi:10.1016/j.amjcard.2008.04.048. PMID 18773998.
- ↑ Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B; American College of Cardiology; American Heart Association Task Force on Practice Guidelines; American College of Chest Physicians; International Society for Heart and Lung Transplantation; Heart Rhythm Society. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation. 2005 Sep 20; 112(12): e154-235. Epub 2005 Sep 13. PMID 16160202
- ↑ Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG et al. (2009) 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 119 (14):1977-2016. DOI:10.1161/CIRCULATIONAHA.109.192064 PMID: 19324967
- ↑ de Lemos JA, McGuire DK, Drazner MH (2003). "B-type natriuretic peptide in cardiovascular disease". Lancet. 362 (9380): 316–22. doi:10.1016/S0140-6736(03)13976-1. PMID 12892964. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Siebert U, Januzzi JL, Beinfeld MT, Cameron R, Gazelle GS (2006). "Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department". The American Journal of Cardiology. 98 (6): 800–5. doi:10.1016/j.amjcard.2006.06.005. PMID 16950189. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Gackowski A, Isnard R, Golmard JL, Pousset F, Carayon A, Montalescot G, Hulot JS, Thomas D, Piwowarska W, Komajda M (2004). "Comparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failure". European Heart Journal. 25 (20): 1788–96. doi:10.1016/j.ehj.2004.07.038. PMID 15474693. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Bayés-Genís A, Santaló-Bel M, Zapico-Muñiz E, López L, Cotes C, Bellido J, Leta R, Casan P, Ordóñez-Llanos J (2004). "N-terminal probrain natriuretic peptide (NT-proBNP) in the emergency diagnosis and in-hospital monitoring of patients with dyspnoea and ventricular dysfunction". European Journal of Heart Failure. 6 (3): 301–8. doi:10.1016/j.ejheart.2003.12.013. PMID 14987580. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, Clopton P, Alberto J, Hlavin P, Maisel AS (2001). "Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting". Journal of the American College of Cardiology. 37 (2): 379–85. PMID 11216950. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Worster A, Balion CM, Hill SA, Santaguida P, Ismaila A, McKelvie R, Reichert SM, McQueen MJ, Booker L, Raina PS (2008). "Diagnostic accuracy of BNP and NT-proBNP in patients presenting to acute care settings with dyspnea: a systematic review". Clinical Biochemistry. 41 (4–5): 250–9. doi:10.1016/j.clinbiochem.2007.08.008. PMID 17915204. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ O'Donoghue M, Kenney P, Oestreicher E, Anwaruddin S, Baggish AL, Krauser DG, Chen A, Tung R, Cameron R, Januzzi JL (2007). "Usefulness of aminoterminal pro-brain natriuretic peptide testing for the diagnostic and prognostic evaluation of dyspneic patients with diabetes mellitus seen in the emergency department (from the PRIDE Study)". The American Journal of Cardiology. 100 (9): 1336–40. doi:10.1016/j.amjcard.2007.06.020. PMID 17950786. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help) - ↑ Silvers SM, Howell JM, Kosowsky JM, Rokos IC, Jagoda AS (2007). "Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with acute heart failure syndromes". Annals of Emergency Medicine. 49 (5): 627–69. doi:10.1016/j.annemergmed.2006.10.024. PMID 17408803. Retrieved 2012-04-05. Unknown parameter
|month=ignored (help)